Clinical Trials
6 trialsNCT00425555 2021-08-20
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma
Novartis
Phase 2 Completed
NCT00490776 2021-08-18
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Novartis
Phase 2 Terminated
NCT00918333 2020-03-10
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00962507 2013-02-15
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed
NCT00412997 2012-11-27
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Novartis
Phase 1 Completed
NCT00699296 2012-11-27
Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
Novartis
Phase 2 Terminated